BACKGROUND: The EUMDS registry is an unique prospective, longitudinal observational registry enrolling newly diagnosed patients with lower-risk myelodysplastic syndrome (MDS) from 17 European countries from both university hospitals and smaller regional hospitals. OBJECTIVE: The aim of this study was to describe the usage and clinical impact of erythropoiesis-stimulating agents (ESAs) in 1696 patients enrolled between 2008 and 2014. METHODS: The effects of ESAs on outcomes were assessed using proportional hazards models weighting observations by propensity to receive ESA treatment within a subset of anaemic patients with or without a regular transfusion need. RESULTS: ESA treatment (median duration of 27.5 months, range 0-77 months) was administered to 773 patients (45.6%). Outcomes were assessed in 897 patients (484 ESA treated and 413 untreated). ESA treatment was associated with a nonsignificant survival benefit (HR 0.82, 95% CI: 0.65-1.04, P = 0.09); this benefit was larger amongst patients without prior transfusions (P = 0.07). Amongst 539 patients for whom response to ESA treatment could be defined, median time to first post-ESA treatment transfusion was 6.1 months (IQR: 4.3-15.9 months) in those transfused before ESA treatment compared to 23.3 months (IQR: 7.0-47.8 months) in patients without prior transfusions (HR 2.4, 95% CI: 1.7-3.3, P < 0.0001). Responding patients had a better prognosis in terms of a lower risk of death (HR 0.65, 95% CI: 0.45-0.893, P = 0.018), whereas there was no significant effect on the risk of progression to acute myeloid leukaemia (HR 0.71, 95% CI: 0.39-1.29, P = 0.27). CONCLUSION: Appropriate use of ESAs can significantly delay the onset of a regular transfusion need in patients with lower-risk MDS.

Clinique Universitaire d'hématologie CHU de Grenoble Université Grenoble Grenoble France

Department of Clinical Hematology Institute of Hematology and Blood Transfusion Praha Czech Republic

Department of Hematology Hospital Universitario y Politécnico La Fe Valencia Spain

Department of Hematology Oncology Fondazione IRCCS Policlinico San Matteo University of Pavia Pavia Italy

Department of Hematology Radboud university medical center Nijmegen the Netherlands

Department of Hematology VU Institute of Cancer and Immunology VU University Medical Center Amsterdam the Netherlands

Department of Internal Medicine 5 Innsbruck Medical University Innsbruck Austria

Department of Medicine A Tel Aviv Sourasky Medical Center Tel Aviv Israel

Department of Medicine Division of Hematology Karolinska Institutet Stockholm Sweden

Department of Medicine Division of Hematology University of Patras Medical School Patras Greece

Department of Medicine Section of Hematology and Coagulation Sahlgrenska University Hospital Gothenburg Sweden

Department of Tumor Immunology Nijmegen Center for Molecular Life Sciences Radboud university medical center Nijmegen the Netherlands

Epidemiology and Cancer Statistics Group Department of Health Sciences University of York York UK

Service d'Hématologie Hôpital Saint Louis Assistance Publique des Hôpitaux de Paris and Université Paris 7 Paris France

St James's Institute of Oncology Leeds Teaching Hospitals Leeds UK

Zobrazit více v PubMed

Jädersten M, Montgomery S, Dybedal I, Porwit‐MacDonald A, Hellström‐Lindberg E. Long‐term outcome of treatment of anemia in MDS with erythropoietin and G‐CSF. Blood 2005; 106: 803–11. PubMed

Jädersten M, Malcovati L, Dybedal I et al Erythropoietin and granulocyte‐colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. J Clin Oncol 2008; 26: 3607–13. PubMed

Hellström‐Lindberg E, Gulbrandsen N, Lindberg G et al A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony‐stimulating factor: significant effects on quality of life. Br J Haematol 2003; 120: 1037–46. PubMed

Nilsson‐Ehle H, Birgegård G, Samuelsson J et al Quality of life, physical function and MRI T2* in elderly low‐risk MDS patients treated to a haemoglobin level of ≥120 g/L with darbepoetin alfa ± filgrastim or erythrocyte transfusions. Eur J Haematol 2011; 87: 244–52. PubMed

Park S, Grabar S, Kelaidi C et al Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G‐CSF: the GFM experience. Blood 2008; 111: 574–82. PubMed

Kjeldsen L, Dybedal I, Hellström‐Lindberg E et al Guidelines for the diagnosis and treatment of Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia from the Nordic MDS Group 2014 [updated 1st of February 2014]. 2014.

Killick SB, Carter C, Culligan D et al Guidelines for the diagnosis and management of adult myelodysplastic syndromes. Br J Haematol 2014; 164: 503–25. PubMed

Malcovati L, Hellström‐Lindberg E, Bowen D et al Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet.. Blood 2013; 122: 2943–64. PubMed PMC

Greenberg PL, Attar E, Bennett JM et al Myelodysplastic syndromes: clinical practice guidelines in oncology. J Natl Compr Canc Netw 2013; 11: 838–74. PubMed PMC

Greenberg PL, Stone R, Bejar R et al Myelodysplastic Syndromes, Version 2.2015. J Natl Compr Canc Netw 2015; 13: 261–72. PubMed PMC

Kelaidi C, Beyne‐Rauzy O, Braun T et al High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower‐risk myelodysplastic syndromes: a phase II study by the GFM. Ann Hematol 2013; 92: 621–31. PubMed

Balleari E, Clavio M, Arboscello E et al Weekly standard doses of rh‐EPO are highly effective for the treatment of anemic patients with low‐intermediate 1 risk myelodysplastic syndromes. Leuk Res 2011; 35: 1472–6. PubMed

Park S, Kelaidi C, Sapena R et al Early introduction of ESA in low risk MDS patients may delay the need for RBC transfusion: a retrospective analysis on 112 patients. Leuk Res 2010; 34: 1430–6. PubMed

Greenberg PL, Sun Z, Miller KB et al Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony‐stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996). Blood 2009; 114: 2393–400. PubMed PMC

de Swart L, Smith A, Johnston TW et al Validation of the revised international prognostic scoring system (IPSS‐R) in patients with lower‐risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registry. Br J Haematol 2015; 170: 372–83. PubMed

Cheson BD, Greenberg P, Bennett JM et al Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006; 108: 419–25. PubMed

Hellström‐Lindberg E, Ahlgren T, Beguin Y et al Treatment of anemia in myelodysplastic syndromes with granulocyte colony‐stimulating factor plus erythropoietin: results from a randomized phase II study and long‐term follow‐up of 71 patients. Blood 1998; 92: 68–75. PubMed

Austin P. The use of propensity score methods with survival or time‐to‐event outcomes: reporting measures of effect similar to those used in randomized experiments. Stat Med 2014; 33: 1242–58. PubMed PMC

Cole SR, Hernán M. Adjusted survival curves with inverse probability weights. Comput Methods Programs Biomed 2004; 75: 45–9. PubMed

SSSI Inc . Software 14.1 User's Guide TEC, NC: 2015.

Schemper M, Smith T. A note on quantifying follow‐up in studies of failure time. Control Clin Trials 1996; 17: 343–6. PubMed

World Economic and Financial Surveys World Economic Outlook Database. http://www.imf.org/external/pubs/ft/weo/2014/02/weodata/index.aspx;imf.org. 2015.

Germing U, Strupp C, Kündgen A et al No increase in age‐specific incidence of myelodysplastic syndromes. Haematologica 2004; 89: 905–10. PubMed

Bernasconi P, Klercy C, Boni M, Cavigliano PM, Dambruoso I, Zappatore R. Validation of the new comprehensive cytogenetic scoring system (NCCSS) on 630 consecutive de novo MDS patients from a single institution. Am J Hematol 2013; 88: 120–9. PubMed

Oliva EN, Nobile F, Alimena G et al Darbepoetin alfa for the treatment of anemia associated with myelodysplastic syndromes: efficacy and quality of life. Leuk Lymphoma 2010; 51: 1007–14. PubMed

Goldberg SL, Chen E, Sasane M, Paley C, Guo A, Laouri M. Economic impact on US Medicare of a new diagnosis of myelodysplastic syndromes and the incremental costs associated with blood transfusion need. Transfusion 2013; 52: 2131–8. PubMed

Survival and quality of life in patients with lower risk myelodysplastic syndromes exposed to erythropoiesis-stimulating agents: an observational cohort study

Somatic mutations and DNA methylation identify a subgroup of poor prognosis within lower-risk myelodysplastic syndromes

Novel dynamic outcome indicators and clinical endpoints in myelodysplastic syndrome; the European LeukemiaNet MDS Registry and MDS-RIGHT project perspective

Zobrazit více v PubMed

ClinicalTrials.gov
NCT00600860